Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for advanced-stage disease, remains rare. Cell therapy as a "living drug" has achieved hematological malignancy cures with a high response rate, and significant research efforts have been made to facilitate its translation to solid tumors. Herein, we overview the cellular therapies for RCC focusing on allogeneic hematopoietic stem cell transplantation, T cell receptor gene-modified T cells, chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, lymphokine-activated killer (LAK) cells, γδ T cells, and dendritic cell vaccination. We have also included perspectives for using other recent approaches, such as CAR macrophages, dendritic cell-cytokine induced killer cells and regulatory CAR-T cells to shed light on preclinical development of cell therapy and advancing cell therapy into clinic to achieve cures for RCC.
Molecular cancer. 2024 Jan 09*** epublish ***
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, Najla Santos Pacheco de Campos, Rabia Abbas, Renata Schmieder Pivetta, Nithyassree Murugan, Ghanbar Mahmoodi Chalbatani, Vincent D'Andrea, Wayne A Marasco
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Center for Natural and Human Sciences, Federal University of ABC, Santo Andre, SP, 09210-580, Brazil., Department of Immunology, Mayo Clinic, Scottsdale, AZ, 85259, USA., Department of Surgery, Brigham and Women's Hospital, Boston, MA, 02215, USA., Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. .